Article

Biggest company for name patient program in India

img

The Named Patient Import Program (NPIP) in India is a crucial pathway that allows patients with rare or life-threatening conditions to access medications that are otherwise unavailable in the country. This program enables individuals, known as "named patients," to import drugs that are approved in other countries but not yet licensed or available in India. In a country like India, which is known for its extensive pharmaceutical industry, the NPIP is particularly important in ensuring that patients have access to potentially life-saving treatments that they might not otherwise be able to obtain.

What is the Named Patient Import Program?
The NPIP is designed to help patients who have no other treatment options within India. It offers hope to those suffering from chronic, serious, or rare diseases by allowing them to import medications that have been approved for use in other parts of the world. To participate in this program, patients must meet certain criteria:

  • Personal Use: The medication must be intended solely for the patient’s personal use.
  • Lack of Alternatives: There must be no alternative treatment available in India.
  • Prescription Requirement: A valid prescription from a licensed healthcare professional is required.

Why does the NPIP matter?
Even though India is known as the "pharmacy of the world" due to its strong pharmaceutical production capabilities, there are still certain innovative treatments—especially for rare diseases—that may not be readily available. The managed access program in India fills this gap by allowing doctors and patients to source these necessary medications from around the globe, expanding treatment options for those in desperate need. This is especially critical for conditions that require specialized therapies not yet accessible in the Indian market.

Here are some top pharma companies in India that facilitate the Named Patient Import Program (NPIP):

  • Ikris Pharma Network 
  • MediSourcing
  • PharmaAccess
  • AccessRx

These companies specialize in helping patients access medications that are not available in India through the NPIP, ensuring compliance with regulatory requirements and managing logistics for drug importation.

How does the NPIP Work?
The NPIP operates under the regulatory framework established by the Central Drugs Standard Control Organization (CDSCO) in India. This ensures that the importation of these unlicensed or unapproved Drugs adheres to strict safety and quality standards. Healthcare providers play a key role in this process, helping to verify the medical necessity of the requested medications and guiding patients through the often complex process of drug importation.

The Bigger Picture:
In summary, the Named Patient Import Program is an essential part of India's healthcare system. It offers a vital option for patients facing severe health challenges to access the treatments they need, even when those treatments are not yet available in the country. By facilitating the importation of these life-saving drugs, the NPIP not only improves patient care but also highlights the importance of having a strong regulatory framework to ensure that patients receive safe and effective therapies. As India continues to grow its pharmaceutical sector, programs like the NPIP will remain crucial in bridging the gap between available treatments and patient needs.

FAQ’s 

What are the new trends in the NPIP?
Digital health platforms are streamlining NPIP with online portals for tracking orders and managing documentation.

Are there any new companies in the NPIP space?
New players like GlobalMed Access and MedEx Worldwide are offering enhanced digital solutions and faster medication import services.

How has the NPIP been impacted by global events?
The COVID-19 pandemic increased demand for NPIP services, leading to stronger supply chains and improved regulatory processes.

How are temperature-sensitive medications managed?
Advanced cold chain logistics ensure that temperature-sensitive drugs maintain their efficacy during transport.

Any recent regulatory changes?
The CDSCO has tightened guidelines for documentation and verification, ensuring the safety and authenticity of imported drugs.


References:
https://www.indianpharmanetwork.in/named-patient-import-program-india/
https://www.ibef.org/industry/pharmaceutical-india
https://builtin.com/articles/top-pharma-companies-in-india
https://www.ncbi.nlm.nih.gov/books/NBK499956/
https://en.wikipedia.org/wiki/Pharmaceutical_industry
https://www.f6s.com/companies/patient/india/co

20.08.24

nitin Goswami

Linkedin